Premium
Health related quality of life in a nationally representative sample of haematological patients
Author(s) -
Johnsen Anna T.,
Tholstrup Dorte,
Petersen Morten Aa.,
Pedersen Lise,
Groenvold Mogens
Publication year - 2009
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2009.01250.x
Subject(s) - medicine , quality of life (healthcare) , logistic regression , multiple myeloma , pediatrics , physical therapy , nursing
Objectives: Knowledge of health related quality of life of haematological patients is limited. This study aimed at investigating the prevalence and predictors of symptoms and problems in a representative sample of haematological patients in Denmark. Methods: A random sample of patients with leukaemia, multiple myeloma and advanced lymphoma ( n = 732) received the European Organisation for Research and Treatment of Cancer quality‐of‐life questionnaire (EORTC QLQ‐C30). Mean scores were calculated. In addition, scores were dichotomised using two thresholds: patients reporting at least ‘a little’ of each EORTC QLQ‐C30 symptom/problem were classified as having a ‘symptom/problem’, and patients reporting at least ‘quite a bit’ were classified as having a ‘severe symptom/problem’. Multiple logistic regression was used to identify predictors. Results: In total, 470 (64%) patients participated. The most frequent symptoms/problems were fatigue (55%; severe 20%), reduced role function (49%; severe 23%), insomnia (46%; severe 15%), and pain (37%; severe 15%). Older patients and patients in active antineoplastic treatment had more symptoms and problems. There was only little evidence of social inequalities. Conclusion: This is probably the first nationally representative study of symptoms and problems in haematological patients. These patients have symptoms/problems that deserve attention. Health related quality of life is an important issue in haematological malignancies.